JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes

JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes Key Dates: February 13, 2013: Expressions of interest (EOI) due date (EOIs must be submitted via the proposalCentral website: https://proposalcentral.altum.com) March 8, 2013: EOI decision notification April 15, 2013: Full application due date (for accepted EOIs) July 2013: Award notification Purpose of Request JDRF is soliciting expressions of interest (EOI) for the discovery, development, pre-clinical or pilot clinical testing of novel antigen-specific therapeutic approaches designed to induce durable immunoregulation for human type 1 diabetes (T1D). JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential. Immunotherapeutic approaches for preventing or halting T1D have involved both antigen-specific and antigen non-specific interventions. Because T1D results from a failure to maintain immune tolerance to beta cell autoantigens, targeting the immune response to these autoantigens may provide an effective means of preventing and controlling the autoimmune response and avoid the harmful effects associated with non-specific immunosuppression. Clinical data from several independent trials has provided compelling evidence that current immunomodulatory approaches are not effective at preventing T1D or a...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding